# Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

> **NCT06492408** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 90 (estimated)

## Conditions studied

- Hepatic Cancer
- Surgery

## Interventions

- **DRUG:** ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab

## Key facts

- **NCT ID:** NCT06492408
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2028-12-30
- **Final completion:** 2033-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06492408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06492408, "Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06492408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*